You are here:Home-Chemical Inhibitors & Agonists-Cell Cycle/DNA Damage-Cyclin-dependent Kinase (CDK)-Abemaciclib
Abemaciclib

Chemical Structure : Abemaciclib

CAS No.: 1231929-97-7

Abemaciclib (LY2835219, LY 2835219)

Catalog No.: PC-20589Not For Human Use, Lab Use Only.

Abemaciclib (LY2835219) is a potent, selective and competitive ATP CDK4/6 inhibitor with Ki values of 0.6 and 2.4 nM for CDK4/cyclin D1 and CDK6/cyclin D1, respectively.

Packing Price Stock Quantity
25 mg $198 In stock
100 mg $498 In stock
200 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Abemaciclib (LY2835219) is a potent, selective and competitive ATP CDK4/6 inhibitor with Ki values of 0.6 and 2.4 nM for CDK4/cyclin D1 and CDK6/cyclin D1, respectively.
Abemaciclib (LY2835219) inhibits CDK4/cyclin D1 and CDK6/cyclin D1 with IC50 of 2 and 10 nM, respectively, with high selectivity against CDK1/cyclin B1, CDK2/cyclin E, and CDK7/Mat1/cyclin H.
Abemaciclib (LY2835219) is a potent inhibitor of Rb phosphorylation (IC50=120 nM) in colo-205 cells, induces a complete cell cycle arrest and suppresses expression of several Rb-E2F-regulated proteins.
Abemaciclib (LY2835219) inhibits tumor growth in human tumor xenografts representing different histologies in tumor-bearing mice.
Abemaciclib (LY2835219) in combination with gemcitabine enhanced in vivo antitumor activity without a G1 cell cycle arrest in calu-6 xenografts.

Physicochemical Properties

M.Wt 506.61
Formula C27H32F2N8
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine

References

1. Tate SC, et al. Clin Cancer Res. 2014 Jul 15;20(14):3763-74.

2. Gelbert LM, et al. Invest New Drugs. 2014 Oct;32(5):825-37.

3. Yadav V, et al. Mol Cancer Ther. 2014 Oct;13(10):2253-63.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: